Date receipt dossier
Company / Sponsor
Vion Pharmaceuticals, Inc.
Phase
I
Treated organism
Humans
Indication category
Cancer therapy
Disease
Non-hematologic malignancies
Therapeutic approach
Tumor colonization
Genetic modification
Not relevant
Method of transfer of nucleic acid of interest
Not relevant
Administered biological material
Genetically modified Salmonella typhimurium bacillus
Route of administration
Intratumoral
Locations in Belgium
Universitair Ziekenhuis Gasthuisberg, Leuven
Type of procedure
Contained use only
Notes
Trial never started in Belgium
Pharmaceutical study code
CLI-007